Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in AR-Positive Salivary Cancers
NCT02749903Phase 2Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in salivary gland cancer (SGC), sponsored by Cancer and Leukemia Group B. Started Sep 2016; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT02749903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02749903.